PT  - JOURNAL ARTICLE
AU  - Ferhan Qureshi
AU  - Wayne Hu
AU  - Louisa Loh
AU  - Hemali Patel
AU  - Maria DeGuzman
AU  - Michael Becich
AU  - Fatima Rubio da Costa
AU  - Victor Gehman
AU  - Fujun Zhang
AU  - John Foley
AU  - Tanuja Chitnis
TI  - Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis
AID  - 10.1101/2022.05.23.22275201
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.05.23.22275201
4099  - http://medrxiv.org/content/early/2023/01/25/2022.05.23.22275201.short
4100  - http://medrxiv.org/content/early/2023/01/25/2022.05.23.22275201.full
AB  - Purpose To characterize and analytically validate the MSDA Test, a multi-protein, serum-based biomarker assay developed using Olink® PEA methodology.Experimental design Two lots of the MSDA Test panel were manufactured and subjected to a comprehensive analytical characterization and validation protocol to detect biomarkers present in the serum of patients with MS. Biomarker concentrations were incorporated into a final algorithm used for calculating four Disease Pathway scores (Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity) and an overall Disease Activity score.Results Analytical characterization demonstrated that the multi-protein panel satisfied the criteria necessary for a fit-for-purpose validation considering the assay’s intended clinical use. This panel met acceptability criteria for 18 biomarkers included in the final algorithm out of 21 biomarkers evaluated. VCAN was omitted based on factors outside of analytical validation; COL4A1 and GH were excluded based on imprecision and diurnal variability, respectively. Performance of the four Disease Pathway and overall Disease Activity scores met the established acceptability criteria.Conclusions and clinical relevance Analytical validation of this multi-protein, serum-based assay is the first step in establishing its potential utility as a quantitative, minimally invasive, and scalable biomarker panel to enhance the standard of care for patients with MS.What is known and what is new in your work?What’s knownMultiple sclerosis (MS) has a complex disease course with variable clinical outcomes; early diagnosis and treatment are critical to management of MS.One key focus in MS research is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to track pathogenesis, disease activity, and disease progression, which may lead to individualized disease management and improved quality of care.There currently are no validated clinical tests that leverage multiple blood biomarkers to track disease activity or progression in patients with MS.What’s newThe MS Disease Activity (MSDA) Test is a multi-protein, serum-based biomarker assay designed to quantitatively measure disease activity using the protein levels of biomarkers present in the serum of patients with MS.In this study, we evaluated 21 biomarkers, 18 of which were selected for inclusion in the MSDA Test, and extensively characterized the MSDA Test (individual biomarkers and algorithmic scores) by establishing the accuracy, precision, sensitivity, and robustness of the assay.This study serves as a critical first step in the validation of this multi-protein, serum-based assay, which will be a quantitative, minimally invasive, and scalable tool to improve MS disease management.Clinical relevance Multiple sclerosis (MS) is a chronic, neurodegenerative, immune-mediated disease of the CNS. MS has a complex disease course with variable clinical outcomes. Although many treatments are effective in early stages of the relapsing/remitting form of the disease, early diagnosis and treatment are critical to managing disease activity and slowing disease progression. One of the major areas of focus in MS research is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to track pathogenesis, disease activity, and disease progression, which can lead to individualized disease management and improved quality of care. Currently, there are no validated clinical tests that leverage multiple blood biomarkers to track disease activity or progression in patients with MS. Herein, we describe the analytical characterization and validation of a multi-protein, serum-based assay panel developed using Olink® PEA methodology. We demonstrate the extensive characterization of this multi-protein, serum-based assay and establish its accuracy, precision, sensitivity, and robustness. This report will be followed by a complementary clinical validation study investigating the correlation between the proteomic assay results and relevant clinical and radiographic endpoints for patients with MS.Competing Interest StatementF. Qureshi, W. Hu, L. Loh, H. Patel and M. DeGuzman are employees of Octave Bioscience, Inc. M. Becich, F. Rubio da Costa, V. Gehman, and F. Zhang were employees of Octave Bioscience, Inc. at the time the study was completed. J. Foley has received research support from Biogen, Novartis, Adamas, Octave Bioscience, Inc., Genentech, and Mallinckrodt, received speakers honoraria and acted as a consultant for EMD Serono, Genzyme, Novartis, Biogen, and Genentech, and has equity interest in Octave Bioscience Inc., and is the founder of InterPro Biosciences. T. Chitnis has received compensation for consulting from Biogen, Novartis Pharmaceuticals, Roche Genentech, and Sanofi Genzyme, and received research support from the National Institutes of Health, National MS Society, US Department of Defense, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Novartis Pharmaceuticals, Octave Bioscience, Inc., Roche Genentech, and Tiziana Life Sciences.Funding StatementThe study was funded by Octave Bioscience, Inc. and in part by the U.S. Department of Defense (W81XWH2110633 to T Chitnis).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used both publicly available data and data acquired under institutional agreement. Serum samples from publicly available sources were analyzed for analytical validation experiments. Serum samples from patients with multiple sclerosis (MS) were analyzed during the assay development and validation process to establish the MS reference ranges for each analyte. These samples came from the following institutional sources: Accelerated Cure Project (Waltham, MA, USA), Brigham and Women's Hospital (Boston, MA, USA), University of California San Francisco (San Francisco, CA, USA), University Hospital Basel (Basel, Switzerland), American University Beirut (Beirut, Lebanon), University of Massachusetts (Boston, MA, USA), University of Pittsburgh (Pittsburgh, PA, USA) and Rocky Mountain Multiple Sclerosis Clinic (Salt Lake City, UT, USA). Data were acquired under institutional agreement and the study was approved by each institutional review board. All patients provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to data can be provided after a research proposal is submitted to the corresponding author and a data sharing agreement is in place.%CVpercent coefficient of variationAPLP1amyloid beta precursor-like protein 1CCL20C-C motif chemokine ligand 20CD6cluster of differentiation 6CDCP1CUB domain-containing protein 1Cmaxmaximum concentrationCNScentral nervous systemCNTN2contactin 2COL4A1collagen type IV alpha-1concconcentrationCSFcerebrospinal fluidCXCL9chemokine (C-X-C motif) ligand 9 (MIG)CXCL13chemokine (C-X-C motif) ligand 13DMTdisease-modifying therapyDNAdeoxyribonucleic acidFLRT2fibronectin leucine-rich repeat transmembrane proteinGd+gadolinium positiveGFAPglial fibrillary acidic protein;GHgrowth hormoneHAMAhuman anti-mouse antibodiesHClhydrochlorideIL-12βinterleukin-12 subunit betaLLOQlower limit of quantitationLOQlimit of quantitationmAbmonoclonal antibodyMaxmaximumMinminimumMOGmyelin oligodendrocyte glycoproteinMRImagnetic resonance imagingMSmultiple sclerosisMSDAMultiple Sclerosis Disease ActivityNasodiumNfLneurofilament light chainOPGosteoprotegerinOPNosteopontinPCRpolymerase chain reactionPEAProximity Extension AssayPRTGprotogeninqPCRquantitative polymerase chain reactionR2coefficient of determinationRArheumatoid arthritisRFrheumatoid factorSDstandard deviationSERPINA9serpin family A member 9TNFRSF10Atumor necrosis factor receptor superfamily member 10A (TRAIL-R1)TNFSF13Btumor necrosis factor superfamily member 13B (BAFF)ULOQupper limit of quantitationVCANversican core protein